{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T19:35:46Z","timestamp":1794512146838,"version":"4.9.1"},"reference-count":70,"publisher":"European Respiratory Society (ERS)","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Breathe"],"accepted":{"date-parts":[[2025,3,10]]},"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:p>Idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) are characterised by an irreversible progression of pulmonary fibrosis and functional lung decline. Current antifibrotic therapies (nintedanib and pirfenidone for IPF and nintedanib for PPF) can reduce disease progression but not halt or reverse it. PPF and IPF share common pathophysiological pathways that need to be further elucidated for the development of novel therapeutic strategies. The educational aim of this review is to explain the pathogenic pathways that have led to the discovery of new therapeutic agents and their favourable implementation in phase 2 and 3 studies. This includes phosphodiesterase 4 inhibitors, \u03b1v\u03b26 and \u03b1v\u03b21 integrin inhibitors, lymphosphatidic acid antagonists, inhaled treprostinil, hedgehog inhibitors, tyrosine kinase inhibitors and angiotensin type 2 receptor agonists. The aim is also to better understand current therapeutic challenges and future perspectives, including cellular therapies, exosomes and their cargoes, as well as the integration of transcriptomics and proteomics, plus gene therapy.<\/jats:p>","DOI":"10.1183\/20734735.0259-2024","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T08:26:11Z","timestamp":1750148771000},"page":"240259","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":30,"title":["A new era in the treatment of progressive fibrosing interstitial lung diseases"],"prefix":"10.1183","volume":"21","author":[{"given":"Anna","family":"Denis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiota","family":"Tsiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Guiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argyris","family":"Tzouvelekis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"key":"2025061701250902000_21.2.240259.1","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2025061701250902000_21.2.240259.2","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-021-01791-z"},{"key":"2025061701250902000_21.2.240259.3","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201006-0894CI"},{"key":"2025061701250902000_21.2.240259.4","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201506-1063ST"},{"key":"2025061701250902000_21.2.240259.5","doi-asserted-by":"crossref","first-page":"709","DOI":"10.3390\/ph17060709","article-title":"Pirfenidone and nintedanib in pulmonary fibrosis: lights and shadows","volume":"17","author":"Chianese","year":"2024","journal-title":"Pharmaceuticals"},{"key":"2025061701250902000_21.2.240259.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402584"},{"key":"2025061701250902000_21.2.240259.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60405-4"},{"key":"2025061701250902000_21.2.240259.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402582"},{"key":"2025061701250902000_21.2.240259.9","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1007\/s12325-022-02145-x","article-title":"Meta-analysis of effect of nintedanib on reducing FVC decline across interstitial lung diseases","volume":"39","author":"Bonella","year":"2022","journal-title":"Adv Ther"},{"key":"2025061701250902000_21.2.240259.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.06.049"},{"key":"2025061701250902000_21.2.240259.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908681"},{"key":"2025061701250902000_21.2.240259.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903076"},{"key":"2025061701250902000_21.2.240259.13","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30036-9"},{"key":"2025061701250902000_21.2.240259.14","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00423-2022"},{"key":"2025061701250902000_21.2.240259.15","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1513\/AnnalsATS.202103-342OC","article-title":"Pirfenidone in progressive pulmonary fibrosis: a systematic review and meta-analysis","volume":"19","author":"Ghazipura","year":"2022","journal-title":"Ann Am Thorac Soc"},{"key":"2025061701250902000_21.2.240259.16","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30554-3"},{"key":"2025061701250902000_21.2.240259.17","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(19)30341-8"},{"key":"2025061701250902000_21.2.240259.18","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2022-219391"},{"key":"2025061701250902000_21.2.240259.19","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2016-103973"},{"key":"2025061701250902000_21.2.240259.20","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1007\/s11010-023-04845-6","article-title":"Idiopathic pulmonary fibrosis (IPF): disease pathophysiology, targets, and potential therapeutic interventions","volume":"479","author":"Saha","year":"2024","journal-title":"Mol Cell Biochem"},{"key":"2025061701250902000_21.2.240259.21","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1164\/rccm.202401-0238SO","article-title":"Genetics and genomics of pulmonary fibrosis: charting the molecular landscape and shaping precision medicine","volume":"210","author":"Adegunsoye","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2025061701250902000_21.2.240259.22","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.03187-2021"},{"key":"2025061701250902000_21.2.240259.23","doi-asserted-by":"publisher","DOI":"10.1007\/s13665-018-0210-7"},{"key":"2025061701250902000_21.2.240259.24","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190103"},{"key":"2025061701250902000_21.2.240259.25","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1164\/rccm.202403-0636OC","article-title":"Bexotegrast in patients with idiopathic pulmonary fibrosis: the INTEGRIS-IPF clinical trial","volume":"210","author":"Lancaster","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2025061701250902000_21.2.240259.26","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-021-01863-0"},{"key":"2025061701250902000_21.2.240259.27","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(98)00331-1"},{"key":"2025061701250902000_21.2.240259.28","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200905-0674OC"},{"key":"2025061701250902000_21.2.240259.29","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.22529"},{"key":"2025061701250902000_21.2.240259.30","doi-asserted-by":"crossref","first-page":"173508","DOI":"10.1016\/j.ejphar.2020.173508","article-title":"A novel phosphodiesterase 4 inhibitor, AA6216, reduces macrophage activity and fibrosis in the lung","volume":"885","author":"Matsuhira","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"2025061701250902000_21.2.240259.31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201737"},{"key":"2025061701250902000_21.2.240259.32","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2022-001563"},{"key":"2025061701250902000_21.2.240259.33","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2022-001580"},{"key":"2025061701250902000_21.2.240259.34","doi-asserted-by":"publisher","DOI":"10.1124\/pr.110.003111"},{"key":"2025061701250902000_21.2.240259.35","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2012-0004OC"},{"key":"2025061701250902000_21.2.240259.36","doi-asserted-by":"publisher","DOI":"10.1513\/pats.201201-005AW"},{"key":"2025061701250902000_21.2.240259.37","doi-asserted-by":"publisher","DOI":"10.1038\/nm1685"},{"key":"2025061701250902000_21.2.240259.38","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2466-14-5"},{"key":"2025061701250902000_21.2.240259.39","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1001\/jama.2023.5355","article-title":"Ziritaxestat, a novel autotaxin inhibitor, and lung function in idiopathic pulmonary fibrosis: the ISABELA 1 and 2 randomized clinical trials","volume":"329","author":"Maher","year":"2023","journal-title":"JAMA"},{"key":"2025061701250902000_21.2.240259.40","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1164\/rccm.202405-0977OC","article-title":"Efficacy and safety of admilparant, an LPA(1) antagonist in pulmonary fibrosis: a phase 2 randomized clinical trial","volume":"211","author":"Corte","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2025061701250902000_21.2.240259.41","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1007\/s12325-022-02229-8","article-title":"The antifibrotic effects of inhaled treprostinil: an emerging option for ILD","volume":"39","author":"Kolb","year":"2022","journal-title":"Adv Ther"},{"key":"2025061701250902000_21.2.240259.42","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2005-0289OC"},{"key":"2025061701250902000_21.2.240259.43","doi-asserted-by":"crossref","first-page":"2045894019881954","DOI":"10.1177\/2045894019881954","article-title":"Orotracheal treprostinil administration attenuates bleomycin-induced lung injury, vascular remodeling, and fibrosis in mice","volume":"9","author":"Nikitopoulou","year":"2019","journal-title":"Pulm Circ"},{"key":"2025061701250902000_21.2.240259.44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2008470"},{"key":"2025061701250902000_21.2.240259.45","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/S2213-2600(21)00165-X","article-title":"Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study","volume":"9","author":"Nathan","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2025061701250902000_21.2.240259.46","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23010171"},{"key":"2025061701250902000_21.2.240259.47","first-page":"A1056","volume-title":"Am J Respir Crit Care Med","volume":"209","author":"Maher","year":"2024"},{"key":"2025061701250902000_21.2.240259.48","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13045-018-0664-7","article-title":"Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development","volume":"11","author":"Shen","year":"2018","journal-title":"J Hematol Oncol"},{"key":"2025061701250902000_21.2.240259.49","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/jphp.13183","article-title":"Anlotinib attenuated bleomycin-induced pulmonary fibrosis via the TGF-\u03b21 signalling pathway","volume":"72","author":"Ruan","year":"2020","journal-title":"J Pharm Pharmacol"},{"key":"2025061701250902000_21.2.240259.50","doi-asserted-by":"crossref","first-page":"115839","DOI":"10.1016\/j.bcp.2023.115839","article-title":"Catch your breath: The protective role of the angiotensin AT2 receptor for the treatment of idiopathic pulmonary fibrosis","volume":"217","author":"Young","year":"2023","journal-title":"Biochem Pharmacol"},{"key":"2025061701250902000_21.2.240259.51","first-page":"A1055","volume-title":"Am J Respir Crit Care Med","volume":"209","author":"Ganslandt","year":"2024"},{"key":"2025061701250902000_21.2.240259.52","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/art.42861","article-title":"2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"2025061701250902000_21.2.240259.53","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151322"},{"key":"2025061701250902000_21.2.240259.54","first-page":"0520","article-title":"Combination therapy of mycophenolate mofetil and pirfenidone vs. mycophenolate alone: results from the Scleroderma Lung Study III [abstract]","volume":"74","author":"Khanna","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2025061701250902000_21.2.240259.55","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/art.40358","article-title":"Belimumab for the treatment of early diffuse systemic sclerosis: results of a randomized, double-blind, placebo-controlled, pilot trial","volume":"70","author":"Gordon","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2025061701250902000_21.2.240259.56","first-page":"PA419","article-title":"Efzofitimod: a novel therapeutic candidate for SSc-ILD","volume":"62: Suppl. 67","author":"Siefker","year":"2023","journal-title":"Eur Respir J"},{"key":"2025061701250902000_21.2.240259.57","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/BOR.0000000000001007","article-title":"Updates on interstitial lung disease and other selected extra-articular manifestations of rheumatoid arthritis","volume":"36","author":"Myasoedova","year":"2024","journal-title":"Curr Opin Rheumatol"},{"key":"2025061701250902000_21.2.240259.58","doi-asserted-by":"crossref","first-page":"103582","DOI":"10.1016\/j.autrev.2024.103582","article-title":"Practical guidance for the early recognition and follow-up of patients with connective tissue disease-related interstitial lung disease","volume":"23","author":"Guiot","year":"2024","journal-title":"Autoimmun Rev"},{"key":"2025061701250902000_21.2.240259.59","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1002\/art.42162","article-title":"A risk score to detect subclinical rheumatoid arthritis-associated interstitial lung disease","volume":"74","author":"Juge","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2025061701250902000_21.2.240259.60","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(22)00260-0"},{"key":"2025061701250902000_21.2.240259.61","doi-asserted-by":"crossref","first-page":"1096203","DOI":"10.3389\/fmed.2022.1096203","article-title":"Clinical features and outcomes of patients with myositis associated-interstitial lung disease","volume":"9","author":"Karampitsakos","year":"2022","journal-title":"Front Med"},{"key":"2025061701250902000_21.2.240259.62","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.04.007"},{"key":"2025061701250902000_21.2.240259.63","doi-asserted-by":"crossref","first-page":"1445923","DOI":"10.3389\/fphar.2024.1445923","article-title":"Lung fibrosis in sarcoidosis. Is there a place for antifibrotics?","volume":"15","author":"B\u0105czek","year":"2024","journal-title":"Front Pharmacol"},{"key":"2025061701250902000_21.2.240259.64","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0000000000000301"},{"key":"2025061701250902000_21.2.240259.65","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00536-2024"},{"key":"2025061701250902000_21.2.240259.66","doi-asserted-by":"crossref","first-page":"639657","DOI":"10.3389\/fcell.2021.639657","article-title":"Therapeutic applications of mesenchymal stem cells in idiopathic pulmonary fibrosis","volume":"9","author":"Yang","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"2025061701250902000_21.2.240259.67","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12931-023-02435-0","article-title":"Integrative multi-omics analysis reveals novel idiopathic pulmonary fibrosis endotypes associated with disease progression","volume":"24","author":"Ruan","year":"2023","journal-title":"Respir Res"},{"key":"2025061701250902000_21.2.240259.68","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1186\/s12964-024-01713-8","article-title":"CRISPR\/Cas9 gene editing: a novel strategy for fighting drug resistance in respiratory disorders","volume":"22","author":"Hussen","year":"2024","journal-title":"Cell Commun Signal"},{"key":"2025061701250902000_21.2.240259.69","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12931-023-02551-x","article-title":"Expression of PD-1\/PD-L1 axis in mediastinal lymph nodes and lung tissue of human and experimental lung fibrosis indicates a potential therapeutic target for idiopathic pulmonary fibrosis","volume":"24","author":"Karampitsakos","year":"2023","journal-title":"Respir Res"},{"key":"2025061701250902000_21.2.240259.70","doi-asserted-by":"crossref","first-page":"104766","DOI":"10.1016\/j.ebiom.2023.104766","article-title":"Precision medicine advances in idiopathic pulmonary fibrosis","volume":"95","author":"Karampitsakos","year":"2023","journal-title":"EBioMedicine"}],"container-title":["Breathe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/20734735.0259-2024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T08:26:19Z","timestamp":1750148779000},"score":1,"resource":{"primary":{"URL":"http:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/20734735.0259-2024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":70,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,6,17]]},"published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1183\/20734735.0259-2024"],"URL":"https:\/\/doi.org\/10.1183\/20734735.0259-2024","relation":{},"ISSN":["1810-6838","2073-4735"],"issn-type":[{"value":"1810-6838","type":"print"},{"value":"2073-4735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]}}}